Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) shares were up 4% during mid-day trading on Monday . The company traded as high as $12.12 and last traded at $12.04. Approximately 201,376 shares traded hands during trading, a decline of 89% from the average daily volume of 1,760,024 shares. The stock had previously closed at […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) insider Charles Mcwherter sold 21,749 shares of the stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $11.43, for a total value of $248,591.07. Following the completion of the sale, the insider now owns 15,000 shares in the company, […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totalling 12,100,000 shares, a growth of 23.5% from the June 15th total of 9,800,000 shares. Based on an average daily volume of 1,880,000 shares, the days-to-cover ratio […]
StockNews.com cut shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) from a hold rating to a sell rating in a research note released on Wednesday morning. A number of other equities research analysts have also recently commented on CBAY. Cantor Fitzgerald lifted their price objective on CymaBay Therapeutics from $13.00 to $15.00 in a research […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction on Friday, July 14th. The stock was sold at an average price of $11.81, for a total transaction of $59,050.00. The sale was disclosed in a document filed with the SEC, which is […]